Susan Galbraith, AstraZeneca EVP of oncology R&D
After decade-plus of failures, AstraZeneca finally gets a win for storied immunotherapy (kind of)
Over the last decade, nearly every Big Pharma has invested hundreds of millions of dollars to develop its own PD-(L)1 drug.
By contrast, the other big cancer immunotherapy — the one that got the whole thing started, that won Jim Allison the Nobel Prize — has largely been a one-company affair. There was Bristol Myers Squibb, their blockbuster Yervoy, and no one else.
Well, almost no one else. One company tried; it just kept failing.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
